IRX-2 is a human cell-derived interleukin (IL)-2 therapeutic for neoadjuvant (presurgical) and adjuvant (post-operative) treatment for advanced head and neck squamous cell cancer. It has multiple active cytokine components that act on various parts of the immune system to activate the entire tumor microenvironment.

The candidate has received both fast-track designation and orphan drug designation from the U.S. Food and Drug Administration for this indication with topline results from a phase IIB clinical trial expected in the first half of 2022.

IRX-2 is also being studied in clinical trials in multiple oncology indications as a monotherapy or as a combination therapy, the firm said.

The merged company will also focus on opportunities in the areas of gene editing and cell therapy through its option agreement with Factor Biosciences and Novellus.